VBL Therapeutics Presents Two Studies on Novel Anti-Angiogenic Vector at 102nd Annual AACR Meeting
TEL AVIV, Israel--(BUSINESS WIRE)--Mar 31, 2011 - VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced two upcoming presentations of preclinical data from the company's VB-111 program at the American Association for Cancer Research (AACR) 102nd Annual Meeting. Eyal Breitbart, Ph.D., vice president of research at VBL Therapeutics, is scheduled to present a poster entitled “VB-111 a Novel Anti-angiogenic Vector and a Promising Treatment for Metastatic Cancer in Combination with Other Anticancer Drugs” on Tuesday, April 5, 2011 at 8:00 a.m. EDT in Orlando, FL. Andrew J. Brenner, M.D., Ph.D., Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, TX, is scheduled to present a poster entitled “Antiangiogenic gene therapy with VB-111 is Active in Glioblastoma Xenografts” on Wednesday, April 6, 2011 at 8:00 a.m. EDT.
VB-111 is a dual-action, anti-angiogenic and Vascular Disruptive Agent (VDA) that utilizes VTS™, VBL's proprietary platform technology for cancer therapy. VB-111 is an intravenously administered VDA that works in a manner akin to a “biological knife” to destroy tumor vasculature, cutting off the blood vessels feeding the tumor. Preclinical pharmacological and toxicology studies of VB-111 showed specificity for the tumor tissue, no significant damage to non-cancerous tissues or to the normal vasculatures in the body, and a more than 90 percent reduction in metastatic lung cancer model with one injection, with similar efficacy in other tumor models. A Phase 1 “all-comers” study of VB-111 in 33 patients with advanced metastatic cancer demonstrated antitumor activity and no effects on liver function or major changes in complete blood count. VB-111 is currently in Phase 2 clinical trials for thyroid cancer and glioblastoma.
About VBL Therapeutics
VBL Therapeutics is an innovative, clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer. VBL has pioneered the Lecinoxoid class of oral anti-inflammatory agents. VB-201 is the company's lead candidate from this program, currently in Phase 2 clinical development in patients with psoriasis and patients with elevated hsCRP levels. In addition, VBL has a proprietary Vascular Targeting System (VTS™) technology platform that has yielded VB-111, a dual-action, anti-angiogenic and vascular disruptive agent (VDA) for cancer, which is currently in Phase 2 clinical trials for thyroid cancer and glioblastoma. The company is based in Tel Aviv, Israel. VBL has 70 granted patents and more than 110 patents pending. For more information on the company, please visit www.vblrx.com.
Contact: Pure Communications
Dan Budwick, 973-271-6085
Posted: March 2011